Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA
| Autor: | Isabel López-Miragaya, Ana Cid Lama, Nuria Estévez, Amparo Iñarrea Fernández, María Oña Navarro, María Teresa Sarán Diez, María Jesús Alvarez Martín, Julio Torres Piñon, Sonia Perez Castro, Mónica Pato Mosquera, María José Lamas González |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Adolescent Uterine Cervical Neoplasms Cervix Uteri Cervical intraepithelial neoplasia Sensitivity and Specificity chemistry.chemical_compound Pregnancy Virology medicine Humans Prospective Studies RNA Messenger Human papillomavirus Prospective cohort study Aged Colposcopy Human papillomavirus 16 Messenger RNA Human papillomavirus 18 medicine.diagnostic_test Diagnostic Tests Routine business.industry Papillomavirus Infections Oncogene Proteins Viral Middle Aged Uterine Cervical Dysplasia medicine.disease Triage Infectious Diseases chemistry RNA Viral Female business DNA |
| Zdroj: | Journal of Medical Virology. 85:1063-1068 |
| ISSN: | 0146-6615 |
| DOI: | 10.1002/jmv.23544 |
| Popis: | High-risk human papillomavirus (HPV) DNA detection provides high sensitivity but low specificity for moderate-grade cervical intraepithelial neoplasia or worse histological identification. A prospective study evaluated mRNA testing efficacy for predicting this histological diagnosis in case of HPV 16 and/or 18 DNA detection. A total of 165 endocervical samples harboring HPV 16 and/or 18 DNA were tested with NucliSENS-EasyQ® HPV E6/E7-mRNA-assay (Biomerieux, Marcy l´Etoile, France). Women with cytological alterations were referred to colposcopy (n = 111). Moderate-grade cervical intraepithelial neoplasia or worse was diagnosed in 25.8% of women presenting atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesions and in 89.8% of women with high-grade squamous intraepithelial lesions. mRNA sensitivity was 81.3% and 84.1%, respectively. Specificity was 52.2%, and 80.0%, respectively. Negative predictive value (NPV) was 88.9% in undetermined or low-grade squamous lesions. Positive predictive value (PPV) was 97.4% in high-grade squamous lesions. mRNA reduced colposcopies by 44.3% in undetermined or low-grade squamous lesions. Direct treatment of mRNA-positive cases reduced 77.5% of colposcopies in high-grade squamous lesions. Women without cytological alterations were followed for 18 months (n = 35), and moderate-grade cervical intraepithelial neoplasia or worse was diagnosed in 34.3%; mRNA sensitivity and specificity were 83.3% and 86.9%, respectively. PPV and NPV were 76.9% and 90.9%, respectively for predicting moderate-grade cervical intraepithelial neoplasia or worse in 18 months. mRNA reduced the number of visits for follow-up in 62.2%. In conclusion, NucliSENS-EasyQ® HPV E6/E7-mRNA-assay (Biomerieux) can serve as a triage test in case of HPV 16 and/or 18 DNA detection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text